// App-Quantinova.ai

TPS363 : SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.

Researchers

Presenter

  • David S. Hong

Principal Investigators

  • Shadia Ibrahim Jalal

  • Elena Elimova

  • Jaffer A. Ajani

  • Mariela A. Blum Murphy

  • Andres Cervantes

  • T.R. Jeffry Evans

  • Haeseong Park

  • Quan Lin

  • Paul Noto

  • Michael Shnaidman

  • Daniel Campbell

  • Marisa Rosenberg

  • Francine Elizabeth Brophy

  • Hassan Danesi

  • David H. Ilson

Medical Centers

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Biomedical Research Institute INCLICA, University of Valencia, Valencia, Spain

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Washington University School of Medicine, St. Louis, MO

  • Adaptimmune, Philadelphia, PA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Canada

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neoplastic meningitis

  • Leptomeningeal Metastasis

  • Solid malignancies

Biomarkers

  • Major Histocompatibility Complex, Class I, A

  • T-cell receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT04044859

  • NCT04752358

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved